Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?
The recent study by Dunlop et al. (1) reports the results of a randomized, placebo-controlled trial of daily oral dosing of a corticotropin-releasing factor type 1 receptor (CRF1 receptor) antagonist, GSK561679 (GlaxoSmithKline; also known as Verucerfont), in women with posttraumatic stress disorder (PTSD) (1). In the trial, 1 28 women with current PTSD of at least moderate severity were randomized to a fixed daily dose of GSK561679 or matching placebo over a 6-week treatment period. There was no difference between GSK561679 and placebo on PTSD symptom severity as measured by the Clinician-Administered PTSD Scale for DSM- IV at the primary outcome.
Source: Biological Psychiatry - Category: Psychiatry Authors: James W. Murrough, Dennis S. Charney Tags: Commentary Source Type: research